IV magnesium sulfate in the treatment of acute severe asthma: A multicenter randomized controlled trial

Robert A. Silverman, Harold Osborn, Jeffrey Runge, E. John Gallagher, William Chiang, James Feldman, Theodore Gaeta, Katherine Freeman, Bruce Levin, Noel Mancherje, Steven Scharf

Research output: Contribution to journalArticle

144 Citations (Scopus)

Abstract

Background: Studies of IV magnesium sulfate as a treatment for acute asthma have had mixed results, with some data suggesting a benefit for acute severe asthma, but not for mild-to-moderate asthma. In a multicenter cohort, this study tests the hypothesis that administration of magnesium sulfate improves pulmonary function in patients with acute severe asthma. Design: Placebo-controlled, double-blind, randomized clinical trial. Setting: Emergency departments (EDs) of eight hospitals. Patients: Patients aged 18 to 60 years presenting with acute asthma and FEV1 ≤30% predicted on arrival to the ED. Intervention: All patients received nebulized albuterol at regular intervals and IV methylprednisolone. Two grams of IV magnesium sulfate or placebo were administered 30 min after ED arrival. The primary efficacy end point was FEV1 at 240 min, and the data analysis was intent to treat. Results: Two hundred forty-eight patients were included, and the mean FEV1 on ED arrival was 22.9% predicted. At 240 min, patients receiving magnesium had a mean FEV1 of 48.2% predicted, compared to 43.5% predicted in the placebo-treated group (mean difference, 4.7%; 95% confidence interval [CI], 0.29 to 9.3%; p = 0.045). A regression model confirmed the effect of magnesium compared to placebo was greater in patients with a lower initial FEV1 (p < 0.05). If the initial FEV1 was <25% predicted, the final FEV1 was 45.3% predicted in the magnesium-treated group and 35.6% predicted in the placebo-treated group (mean difference, 9.7%; 95% CI, 4.0 to 15.3%; p = 0.001). If the initial FEV was ≥25% predicted, magnesium administration was not beneficial; the final FEV1 was 51.1% predicted in the magnesium-treated group and 53.9% predicted in the placebo-treated group (mean difference, -2.9%, 95% CI, -9.4 to 3.7; p = not significant). Overall, the use of magnesium sulfate did not improve hospital admission rates. Conclusion: Administration of 2 g of IV magnesium sulfate improves pulmonary function when used as an adjunct to standard therapy in patients with very severe, acute asthma.

Original languageEnglish (US)
Pages (from-to)489-497
Number of pages9
JournalChest
Volume122
Issue number2
DOIs
StatePublished - 2002

Fingerprint

Magnesium Sulfate
Asthma
Randomized Controlled Trials
Magnesium
Placebos
Hospital Emergency Service
Confidence Intervals
Therapeutics
Lung
Albuterol
Methylprednisolone
Multicenter Studies
Cohort Studies

Keywords

  • Acute disease
  • Asthma
  • Magnesium

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Silverman, R. A., Osborn, H., Runge, J., Gallagher, E. J., Chiang, W., Feldman, J., ... Scharf, S. (2002). IV magnesium sulfate in the treatment of acute severe asthma: A multicenter randomized controlled trial. Chest, 122(2), 489-497. https://doi.org/10.1378/chest.122.2.489

IV magnesium sulfate in the treatment of acute severe asthma : A multicenter randomized controlled trial. / Silverman, Robert A.; Osborn, Harold; Runge, Jeffrey; Gallagher, E. John; Chiang, William; Feldman, James; Gaeta, Theodore; Freeman, Katherine; Levin, Bruce; Mancherje, Noel; Scharf, Steven.

In: Chest, Vol. 122, No. 2, 2002, p. 489-497.

Research output: Contribution to journalArticle

Silverman, RA, Osborn, H, Runge, J, Gallagher, EJ, Chiang, W, Feldman, J, Gaeta, T, Freeman, K, Levin, B, Mancherje, N & Scharf, S 2002, 'IV magnesium sulfate in the treatment of acute severe asthma: A multicenter randomized controlled trial', Chest, vol. 122, no. 2, pp. 489-497. https://doi.org/10.1378/chest.122.2.489
Silverman, Robert A. ; Osborn, Harold ; Runge, Jeffrey ; Gallagher, E. John ; Chiang, William ; Feldman, James ; Gaeta, Theodore ; Freeman, Katherine ; Levin, Bruce ; Mancherje, Noel ; Scharf, Steven. / IV magnesium sulfate in the treatment of acute severe asthma : A multicenter randomized controlled trial. In: Chest. 2002 ; Vol. 122, No. 2. pp. 489-497.
@article{6e6d4a70453d4dcb8eaaf5bb66b98949,
title = "IV magnesium sulfate in the treatment of acute severe asthma: A multicenter randomized controlled trial",
abstract = "Background: Studies of IV magnesium sulfate as a treatment for acute asthma have had mixed results, with some data suggesting a benefit for acute severe asthma, but not for mild-to-moderate asthma. In a multicenter cohort, this study tests the hypothesis that administration of magnesium sulfate improves pulmonary function in patients with acute severe asthma. Design: Placebo-controlled, double-blind, randomized clinical trial. Setting: Emergency departments (EDs) of eight hospitals. Patients: Patients aged 18 to 60 years presenting with acute asthma and FEV1 ≤30{\%} predicted on arrival to the ED. Intervention: All patients received nebulized albuterol at regular intervals and IV methylprednisolone. Two grams of IV magnesium sulfate or placebo were administered 30 min after ED arrival. The primary efficacy end point was FEV1 at 240 min, and the data analysis was intent to treat. Results: Two hundred forty-eight patients were included, and the mean FEV1 on ED arrival was 22.9{\%} predicted. At 240 min, patients receiving magnesium had a mean FEV1 of 48.2{\%} predicted, compared to 43.5{\%} predicted in the placebo-treated group (mean difference, 4.7{\%}; 95{\%} confidence interval [CI], 0.29 to 9.3{\%}; p = 0.045). A regression model confirmed the effect of magnesium compared to placebo was greater in patients with a lower initial FEV1 (p < 0.05). If the initial FEV1 was <25{\%} predicted, the final FEV1 was 45.3{\%} predicted in the magnesium-treated group and 35.6{\%} predicted in the placebo-treated group (mean difference, 9.7{\%}; 95{\%} CI, 4.0 to 15.3{\%}; p = 0.001). If the initial FEV was ≥25{\%} predicted, magnesium administration was not beneficial; the final FEV1 was 51.1{\%} predicted in the magnesium-treated group and 53.9{\%} predicted in the placebo-treated group (mean difference, -2.9{\%}, 95{\%} CI, -9.4 to 3.7; p = not significant). Overall, the use of magnesium sulfate did not improve hospital admission rates. Conclusion: Administration of 2 g of IV magnesium sulfate improves pulmonary function when used as an adjunct to standard therapy in patients with very severe, acute asthma.",
keywords = "Acute disease, Asthma, Magnesium",
author = "Silverman, {Robert A.} and Harold Osborn and Jeffrey Runge and Gallagher, {E. John} and William Chiang and James Feldman and Theodore Gaeta and Katherine Freeman and Bruce Levin and Noel Mancherje and Steven Scharf",
year = "2002",
doi = "10.1378/chest.122.2.489",
language = "English (US)",
volume = "122",
pages = "489--497",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "2",

}

TY - JOUR

T1 - IV magnesium sulfate in the treatment of acute severe asthma

T2 - A multicenter randomized controlled trial

AU - Silverman, Robert A.

AU - Osborn, Harold

AU - Runge, Jeffrey

AU - Gallagher, E. John

AU - Chiang, William

AU - Feldman, James

AU - Gaeta, Theodore

AU - Freeman, Katherine

AU - Levin, Bruce

AU - Mancherje, Noel

AU - Scharf, Steven

PY - 2002

Y1 - 2002

N2 - Background: Studies of IV magnesium sulfate as a treatment for acute asthma have had mixed results, with some data suggesting a benefit for acute severe asthma, but not for mild-to-moderate asthma. In a multicenter cohort, this study tests the hypothesis that administration of magnesium sulfate improves pulmonary function in patients with acute severe asthma. Design: Placebo-controlled, double-blind, randomized clinical trial. Setting: Emergency departments (EDs) of eight hospitals. Patients: Patients aged 18 to 60 years presenting with acute asthma and FEV1 ≤30% predicted on arrival to the ED. Intervention: All patients received nebulized albuterol at regular intervals and IV methylprednisolone. Two grams of IV magnesium sulfate or placebo were administered 30 min after ED arrival. The primary efficacy end point was FEV1 at 240 min, and the data analysis was intent to treat. Results: Two hundred forty-eight patients were included, and the mean FEV1 on ED arrival was 22.9% predicted. At 240 min, patients receiving magnesium had a mean FEV1 of 48.2% predicted, compared to 43.5% predicted in the placebo-treated group (mean difference, 4.7%; 95% confidence interval [CI], 0.29 to 9.3%; p = 0.045). A regression model confirmed the effect of magnesium compared to placebo was greater in patients with a lower initial FEV1 (p < 0.05). If the initial FEV1 was <25% predicted, the final FEV1 was 45.3% predicted in the magnesium-treated group and 35.6% predicted in the placebo-treated group (mean difference, 9.7%; 95% CI, 4.0 to 15.3%; p = 0.001). If the initial FEV was ≥25% predicted, magnesium administration was not beneficial; the final FEV1 was 51.1% predicted in the magnesium-treated group and 53.9% predicted in the placebo-treated group (mean difference, -2.9%, 95% CI, -9.4 to 3.7; p = not significant). Overall, the use of magnesium sulfate did not improve hospital admission rates. Conclusion: Administration of 2 g of IV magnesium sulfate improves pulmonary function when used as an adjunct to standard therapy in patients with very severe, acute asthma.

AB - Background: Studies of IV magnesium sulfate as a treatment for acute asthma have had mixed results, with some data suggesting a benefit for acute severe asthma, but not for mild-to-moderate asthma. In a multicenter cohort, this study tests the hypothesis that administration of magnesium sulfate improves pulmonary function in patients with acute severe asthma. Design: Placebo-controlled, double-blind, randomized clinical trial. Setting: Emergency departments (EDs) of eight hospitals. Patients: Patients aged 18 to 60 years presenting with acute asthma and FEV1 ≤30% predicted on arrival to the ED. Intervention: All patients received nebulized albuterol at regular intervals and IV methylprednisolone. Two grams of IV magnesium sulfate or placebo were administered 30 min after ED arrival. The primary efficacy end point was FEV1 at 240 min, and the data analysis was intent to treat. Results: Two hundred forty-eight patients were included, and the mean FEV1 on ED arrival was 22.9% predicted. At 240 min, patients receiving magnesium had a mean FEV1 of 48.2% predicted, compared to 43.5% predicted in the placebo-treated group (mean difference, 4.7%; 95% confidence interval [CI], 0.29 to 9.3%; p = 0.045). A regression model confirmed the effect of magnesium compared to placebo was greater in patients with a lower initial FEV1 (p < 0.05). If the initial FEV1 was <25% predicted, the final FEV1 was 45.3% predicted in the magnesium-treated group and 35.6% predicted in the placebo-treated group (mean difference, 9.7%; 95% CI, 4.0 to 15.3%; p = 0.001). If the initial FEV was ≥25% predicted, magnesium administration was not beneficial; the final FEV1 was 51.1% predicted in the magnesium-treated group and 53.9% predicted in the placebo-treated group (mean difference, -2.9%, 95% CI, -9.4 to 3.7; p = not significant). Overall, the use of magnesium sulfate did not improve hospital admission rates. Conclusion: Administration of 2 g of IV magnesium sulfate improves pulmonary function when used as an adjunct to standard therapy in patients with very severe, acute asthma.

KW - Acute disease

KW - Asthma

KW - Magnesium

UR - http://www.scopus.com/inward/record.url?scp=18544378154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18544378154&partnerID=8YFLogxK

U2 - 10.1378/chest.122.2.489

DO - 10.1378/chest.122.2.489

M3 - Article

C2 - 12171821

AN - SCOPUS:18544378154

VL - 122

SP - 489

EP - 497

JO - Chest

JF - Chest

SN - 0012-3692

IS - 2

ER -